XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1

Tian,Xiaohong; Hou,Weijian; Bai,Shuling; Fan,Jun; Tong,Hao; Xu,He

doi:10.3892/ijo.2014.2406

XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1

Authors:
- Xiaohong Tian
- Weijian Hou
- Shuling Bai
- Jun Fan
- Hao Tong
- He Xu
View Affiliations

Affiliations: Department of Tissue Engineering, College of Basic Medical Sciences, China Medical University, Shenyang 110001, P.R. China
Published online on: April 28, 2014 https://doi.org/10.3892/ijo.2014.2406
Pages: 121-128

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. One fundamental issue regarding NB recurrence and metastasis is the maintenance of cancer stem cells (CSCs) stemness. Tankyrase 1 (TNKS1) is overexpressed in several types of cancers and in NB cell lines. XAV939 is a small molecule inhibitor of TNKS1 and can induce apoptosis of NB cells. In this study, we showed that the surface marker CD133 method was more suitable for isolating NB CSCs than the side-population method, and 60 µM etoposide was optimal for enriching NB CSCs. The NB CSCs were demonstrated in juvenescence or stemness state by electron microscopy, which was in line with the characteristics of CSCs. Furthermore, we demonstrated that the expression of the CSCs marker CD133 and migration ability of CSCs decreased after XAV939 treatment or by RNAi‑mediated knockdown of the TNKS1 gene. These findings suggest that XAV939 treatment or RNAi-TNKS1 inhibits the stemness and migration of NB CSCs via the repression of TNKS1, and TNKS1 may be a potential molecular target for eliminating NB CSCs by small molecule drugs.

View Figures

View References

1.	Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science. 197:461–463. 1977. View Article : Google Scholar : PubMed/NCBI
2.	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Huntly BJP and Gilliland DG: Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 5:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Ross RA and Spengler BA: Human neuroblastoma stem cells. Semin Cancer Biol. 17:241–247. 2007. View Article : Google Scholar
5.	Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G and Sabanci A: Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncol. 100:385–395. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Abbott BL: ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells. Clin Adv Hematol Oncol. 4:63–72. 2006.PubMed/NCBI
7.	Nan JN, Hu XG and Li HX: Research progress in tumor stem cells: literature retrieval results based on international database. Chin J Tiss Eng Res. 516:1085–1093. 2012.
8.	Huang SM, Mishina YM, Liu S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature. 461:614–620. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Chen B, Dodge ME, Tang W, et al: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol. 5:100–107. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Xu D, Zheng C, Bergenbrant S, Holm G, Björkholm M, Yi Q and Gruber A: Telomerase activity in plasma cell dyscrasias. Br J Cancer. 84:621–625. 2001. View Article : Google Scholar : PubMed/NCBI
11.	MacNamara B, Wang W, Chen Z, et al: Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin’s lymphomas. Haematologica. 86:386–393. 2001.PubMed/NCBI
12.	Klapper W, Krams M, Qian W, Janssen D and Parwaresch R: Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer. 89:713–719. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Gelmini S, Poggesi M, Distante V, et al: Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett. 216:81–87. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Gelmini S, Poggesi M, Pinzani P, et al: Distribution of tankyrase-1 mRNA expression in colon cancer and its prospective correlation with progression stage. Oncol Rep. 16:1261–1266. 2006.
15.	Gelmini S, Quattrone S, Malentacchi F, et al: Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med. 45:862–866. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Shervington A, Patel R, Lu C, et al: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res. 1134:45–52. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Tian XH, Hou WJ, Fang Y, et al: XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 32:100–109. 2013.PubMed/NCBI
18.	Vangipuram SD, Buck SA and Lyman WD: Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour Biol. 33:2173–2183. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Al-Hajj M and Clarke MF: Self renewal and solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
21.	Lou H and Dean M: Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 26:1357–1360. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Hadnagy A, Gaboury L, Beaulieu R and Balicki D: SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 312:3701–3710. 2006. View Article : Google Scholar : PubMed/NCBI
23.	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
25.	Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
26.	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
27.	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
29.	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumor initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Mahller YY, Williams JP, Baird WH, et al: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One. 4:e42352009. View Article : Google Scholar : PubMed/NCBI
31.	Hemmati HD, Nakano I, Lazareff JA, et al: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 100:15178–15183. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Na YR, Seok SH, Kim DJ, et al: Isolation and characterization of spheroid cells from human malignannt melanoma cell line WM-266-4. Tumor Biol. 30:300–309. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Di Fiore R, Santulli A, Ferrante RD, et al: Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol. 219:301–313. 2009.PubMed/NCBI
34.	Das B, Tsuchida R, Malkin D, Koren G, Baruchel S and Yeger H: Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells. 26:1818–1830. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Marzi I, D’Amico M, Biagiotti T, et al: Purging of the neuroblastoma stem cell compartment and tumor regression on exposure to hypoxia or cytotoxic treatment. Cancer Res. 67:2402–2407. 2007. View Article : Google Scholar : PubMed/NCBI
36.	Deng YW, Fang JS, Li MC, et al: Correlation research between cancer stem cells and the pathological grades of neuroepithelial tumors. J Cent South Uniu (Med Sci). 31:45–51. 2006.PubMed/NCBI
37.	Abbott A: Cancer: the root of the problem. Nature. 442:742–743. 2006. View Article : Google Scholar : PubMed/NCBI
38.	Lindvall C, Bu W, Williams BO and Li Y: Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 3:157–168. 2007. View Article : Google Scholar : PubMed/NCBI
39.	Fu JK, Wang Z and Wei S: Alterations and its mechanisms of Wnt signal pathway in human high-matastatatic large cell lung cancer cell line L9981 by transfecting with Nm23-H1 gene. Chin J Lung Cancer. 12:477–479. 2009.
40.	Nguyen DX, Chiang AC, Zhang XH, et al: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
41.	Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A and Aaronson SA: Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 28:2163–2172. 2009. View Article : Google Scholar : PubMed/NCBI
42.	Sun JZ, Yang XX, Hu NY, Li X, Li FX and Li M: Genetic variants in MMP9 and TGF2 contribute to susceptibility to lung cancer. Chin J Cancer. 23:183–187. 2011. View Article : Google Scholar : PubMed/NCBI
43.	Kim J, You L, Xu Z, et al: Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg. 133:733–737. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Katoh Y and Katoh M: Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med. 19:967–970. 2007.PubMed/NCBI
45.	Horst D, Kriegl L, Engel J, Jung A and Kirchner T: CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer. 45:2034–2040. 2009. View Article : Google Scholar : PubMed/NCBI
46.	Ruck P, Xiao JC, Pietsch T, Von Schweinitz D and Kaiserling E: Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology. 31:324–329. 1997. View Article : Google Scholar : PubMed/NCBI
47.	Karner CM, Merkel CE, Dodge M, Ma Z, Lu J, Chen C, Lum L and Carroll TJ: Tankyrase is necessary for canonical Wnt signaling during kidney development. Dev Dyn. 239:2014–2023. 2010. View Article : Google Scholar
48.	Chung SS, Giehl N, Wu Y and Vadgama JV: STAT3 activation in HER2-overexpressing breast cancer promotes epithelialmesenchymal transition and cancer stem cell traits. Int J Oncol. 44:403–411. 2014.PubMed/NCBI